Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.

CONTEXT In preparation for whole body radioactive iodine scanning, recombinant human TSH (rhTSH) is usually administered as 0.9-mg i.m. injections on 2 consecutive days without regard to age, body size, or other comorbid conditions. OBJECTIVE Our objective was to determine whether the usual adult rhTSH dosing regimen would result in excessive elevations of serum TSH in children and teenagers with thyroid cancer. DESIGN/SETTING/PATIENTS/INTERVENTIONS: A retrospective review identified 53 children and teenagers with thyroid cancer who underwent whole body radioactive iodine (RAI) scanning over a 12-yr period at two major medical centers (34 after thyroid hormone withdrawal and 19 after rhTSH treatment). MAIN OUTCOME MEASURES The dynamic time course of changes in serum TSH after rhTSH administration and/or hypothyroid withdrawal was examined. Peak TSH levels were correlated with age, weight, and body surface area. RESULTS The mean serum TSH at the time of RAI administration was similar in patients undergoing hypothyroid preparation (188 +/- 118 mIU/liter; range, 110-452 mIU/liter) and those treated with rhTSH (134 +/- 75 mIU/liter; range, 32-290 mIU/liter; P = 0.07). Serial determinations after rhTSH injections revealed a mean serum TSH of 268 +/- 76 mU/liter (range, 87-628) at 6 h and 130 +/- 58 mU/liter (range, 67-250) at 24 h after the initial injection, and 361 +/- 78 mU/liter (range 161-524) at 6 h and 134 +/- 44 mU/liter (range, 32-290) at 24 h after the second injection. CONCLUSIONS The mean TSH levels achieved in children after rhTSH injections are remarkably similar to values previously reported in adults despite marked differences in clinical characteristics between children and adults. These data suggest that dose adjustments are not generally required in children and teenagers undergoing rhTSH stimulation for RAI scanning or serum-stimulated thyroglobulin determinations.

[1]  S. Larson,et al.  Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[2]  S. Larson,et al.  A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  L. Braverman,et al.  Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  R. Robbins,et al.  Recombinant Human Thyrotropin and Thyroid Cancer Management , 2003 .

[5]  R. Robbins,et al.  Clinical review 156: Recombinant human thyrotropin and thyroid cancer management. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[7]  L. Braverman,et al.  Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). , 1994, The Journal of clinical endocrinology and metabolism.

[8]  G. Vitale,et al.  Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  S. Larson,et al.  Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.

[10]  E. Mazzaferri,et al.  Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. , 2002, Endocrine-related cancer.